193 related articles for article (PubMed ID: 17010685)
21. Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years of strontium ranelate treatment.
Roschger P; Manjubala I; Zoeger N; Meirer F; Simon R; Li C; Fratzl-Zelman N; Misof BM; Paschalis EP; Streli C; Fratzl P; Klaushofer K
J Bone Miner Res; 2010 Apr; 25(4):891-900. PubMed ID: 20437609
[TBL] [Abstract][Full Text] [Related]
22. Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis.
Meunier PJ; Reginster JY
Osteoporos Int; 2003; 14 Suppl 3():S66-76. PubMed ID: 12730769
[TBL] [Abstract][Full Text] [Related]
23. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis.
Neuprez A; Hiligsmann M; Scholtissen S; Bruyere O; Reginster JY
Adv Ther; 2008 Dec; 25(12):1235-56. PubMed ID: 19066755
[TBL] [Abstract][Full Text] [Related]
24. Strontium ranelate increases cartilage matrix formation.
Henrotin Y; Labasse A; Zheng SX; Galais P; Tsouderos Y; Crielaard JM; Reginster JY
J Bone Miner Res; 2001 Feb; 16(2):299-308. PubMed ID: 11204430
[TBL] [Abstract][Full Text] [Related]
25. Strontium as therapy for osteoporosis.
Marie PJ
Curr Opin Pharmacol; 2005 Dec; 5(6):633-6. PubMed ID: 16183330
[TBL] [Abstract][Full Text] [Related]
26. Increased cartilage type II collagen degradation in patients with osteogenesis imperfecta used as a human model of bone type I collagen alterations.
Rousseau JC; Chevrel G; Schott AM; Garnero P
Bone; 2010 Apr; 46(4):897-900. PubMed ID: 20005316
[TBL] [Abstract][Full Text] [Related]
27. [Strontium ranelate--new paradigm in the treatment of postmenopausal osteoporosis].
Korsić M; Giljević Z; Kastelan D
Lijec Vjesn; 2006; 128(5-6):180-2. PubMed ID: 16910420
[TBL] [Abstract][Full Text] [Related]
28. Clinical effects of strontium ranelate in women with postmenopausal osteoporosis.
Delmas PD
Osteoporos Int; 2005 Jan; 16 Suppl 1():S16-9. PubMed ID: 15578158
[TBL] [Abstract][Full Text] [Related]
29. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro.
Bonnelye E; Chabadel A; Saltel F; Jurdic P
Bone; 2008 Jan; 42(1):129-38. PubMed ID: 17945546
[TBL] [Abstract][Full Text] [Related]
30. Strontium is incorporated into mineral crystals only in newly formed bone during strontium ranelate treatment.
Li C; Paris O; Siegel S; Roschger P; Paschalis EP; Klaushofer K; Fratzl P
J Bone Miner Res; 2010 May; 25(5):968-75. PubMed ID: 19874195
[TBL] [Abstract][Full Text] [Related]
31. Strontium ranelate in the prevention of osteoporotic fractures.
Reginster JY; Malaise O; Neuprez A; Bruyere O
Int J Clin Pract; 2007 Feb; 61(2):324-8. PubMed ID: 17263720
[TBL] [Abstract][Full Text] [Related]
32. Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone.
Farlay D; Boivin G; Panczer G; Lalande A; Meunier PJ
J Bone Miner Res; 2005 Sep; 20(9):1569-78. PubMed ID: 16059629
[TBL] [Abstract][Full Text] [Related]
33. Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis.
Ma YL; Marin F; Stepan J; Ish-Shalom S; Möricke R; Hawkins F; Kapetanos G; de la Peña MP; Kekow J; Martínez G; Malouf J; Zeng QQ; Wan X; Recker RR
Bone; 2011 May; 48(5):972-8. PubMed ID: 21262402
[TBL] [Abstract][Full Text] [Related]
34. Strontium ranelate (Fujisawa/Servier).
Jupsin I; Collette J; Henrotin Y; Bruyere O; Sarlet N; Reginster JY
Curr Opin Investig Drugs; 2005 Apr; 6(4):435-44. PubMed ID: 15898351
[TBL] [Abstract][Full Text] [Related]
35. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials.
Borgström F; Jönsson B; Ström O; Kanis JA
Osteoporos Int; 2006 Dec; 17(12):1781-93. PubMed ID: 17009083
[TBL] [Abstract][Full Text] [Related]
36. [Strontium Ranelate as a new therapeutic agent for osteoporosis].
Imanishi Y; Nishizawa Y
Clin Calcium; 2005 Jan; 15(1):25-8. PubMed ID: 15632469
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy of strontium ranelate for the mineralization of bone in postmenopausal women].
Basurto L; Zárate A; Córdova N; Saucedo R; Galván R; Campos S; Hernández M
Ginecol Obstet Mex; 2009 May; 77(5):227-30. PubMed ID: 19496517
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Inderjeeth CA; Foo AC; Lai MM; Glendenning P
Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
[TBL] [Abstract][Full Text] [Related]
39. [Strontium ranelate: a new therapeutic principle for postmenopausal osteoporosis].
Mosekilde L; Nielsen LR; Vestergaard P
Ugeskr Laeger; 2005 Sep; 167(37):3485-7. PubMed ID: 16159455
[TBL] [Abstract][Full Text] [Related]
40. The action of Strontium ranelate: myth or reality.
Bunyaratavej N
J Med Assoc Thai; 2011 Oct; 94 Suppl 5():S35-7. PubMed ID: 22338924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
